Board of Directors – VISUMPharma

William Gedale, JD, MBA

President & CEO

William “Bill” Gedale holds an AB from Syracuse University, a JD from Fordham Law School, and an MBA from NYU. He has been in the investment business since 1965 and has an history as a consultant and advisor. After serving as Chief Executive Officer of General American Investors and as Managing Director of John W. Bristol & Co., Bill founded Mount Everest Advisors in 1996 where he provided consulting services to Warburg-Pincus Capital Management from which came the $140 million financing of ZymoGenetics. He also facilitated the $350 million funding of Scripps Research Institute by Sandoz (later Novartis) and the $40 millon funding of the Neuroscience Institute of La Jolla. Bill has extensive experience as a board director having served on the boards of Gamco (Gabelli Holding), Allied Clinical Laboratories (acquired by LabCorp), BioReliance Corporation (acquired by Sigma-Aldrich), US Home Health Care, Unilab (acquired by Kelso), KIKA Medical Inc (acquired by Merge Healthcare), and BioArray Solutions (acquired by Immucor). He presently is the chairman of PIN Pharma, Inc., and Promosome.

John Costantino, JD, MBA, CPA

John Costantino is a founding member and manager of Visum Pharma’s parent company, Resilion. A lawyer and CPA, John serves as a director for a family of funds at State Street Bank which includes the former family of mutual funds of General Electric, where he served as Independent Chairman. He also is a board member and part-owner of Kleinfeld Bridal and is a member of the board of advisors of L&R Corporation. John is a senior advisor and a former General Partner of NGN Capital, LLC, a healthcare venture capital company based in New York and Heidelberg, Germany, and with $450 million in total funds. He is also trustee emeritus at Fordham University and is an advisory board member of Fordham Law School Center for Neuroscience and Law. He is a director of the Muscular Dystrophy Association and was Managing Tax Partner in the New York office of Touché Ross and Co., and the Chief Operating Officer of the Conair Corporation. John has been recognized for his contributions to business and the community being awarded the Richard S. Bennett award for ethics, the 2006 Ellis Island Medal of Honor, and, along with his wife, Barbara, the 2018 Fordham University’s Founders Award.

Claudio del Vecchio

Claudio Del Vecchio is an international entrepreneur. He is president of DELV Holdings that invest in diversified industries. For 20 years he served as Chairman and CEO of Brooks Brothers group. Mr. Del Vecchio cam to the United States in 1982. He was Instrumental in transforming Luxottica in to the premier eyewear organization overseeing its IPO on the NYSE in 1990. In 1995, through Luxottica’s purchase of The United States Shoe Corporation, the company acquired LensCrafters, the largest optical retailer in the US, and Casual Corner Group stores. Mr. Del Vecchio assumed ownership of Causal Corner Group in 1997. In December 2001, Mr. Del Vecchio Acquired Brooks Brothers. Mr Del Vecchio has been recognized for his work with many charities. Today, he serves on the board of the Interfaith Nutrition Network, the American Italian Cancer Foundation, Friends of San Patrignano, the Catholic Community Foundation of Long Island in addition to several non-profit organizations. In 2007, he established the Brooks Brothers “Golden Fleece Foundation” which Has raised millions of dollars on behalf of charities including St. Jude’s Children’s Research Hospital and the Make-A-Wish Foundation. In 2012, he was honored by Bryant University, receiving the degree of Doctor of Business Administration. In 2014, he was named in to the Cavalieri Del Lavoro, the highest civilian honor in Italy.

Peter Vanderklish, PhD

Chief Science Officer

Peter has a long track record of expertise and significant contributions in synaptic neurobiology, intellectual disability, neurodegenerative disease, the regulation of local protein synthesis, and target identification. His 25-year career in neuroscience began with graduate work at UC Irvine with Dr. Gary Lynch, where he helped establish that long term potentiation is expressed by changes in the postsynaptic element, and that postsynaptic adhesion molecules play a key role in consolidating such changes via the restructuring of synapses. He did postdoctoral work with Nobel Laureate Dr. Gerald Edelman at Scripps Research in La Jolla after which he directed his own lab at Scripps as a faculty member in the departments of Neuroscience and Molecular Medicine, focusing largely on synaptic mechanisms and target identification in Fragile X Syndrome where he has made foundational contributions. He was appointed to the Neurosciences Institute, a private research organization founded and directed by Dr. Edelman. More recently, Peter has acted as CSO at a company developing novel small molecules to regenerate synaptic density in neurodegenerative disorders and has consulted at a company developing new methods to diagnose neurodegenerative diseases through the eye.

Bernard Peperstraete, MD, MBA

Bernard is a medical entrepreneur having been involved in the investment, start-up, and operation of life science businesses for over 20 years. Currently, Bernard is CEO and co-founder of Acuamark Diagnostics, Inc., a company focused on the early detection of cancer. Prior to Acuamark, Bernard ran ACT Biotech, a cancer therapeutics company acquired by Eddingpharm. Before his time at ACT, he was involved in healthcare venture capital for nearly a decade, most recently as a Partner at NGN Capital. Bernard has served on the boards of Exosome Diagnostics (acquired by Bio-Techne), ACT Biotech (acquired by EddingPharm) and Potentia Pharma (NASDAQ), and was closely involved with a number of transactions among which were Santhera, and Artisan Pharma (acquired by AKP). Prior to completing his MBA at Harvard, Bernard worked on emerging market opportunities at Novartis in Basel, was a Deputy Director at the Tan Tock Seng Hospital in Singapore (during the SARS crisis), and co-founded and ran a contract research business, also in Singapore. In 1999, after serving as a physician and receiving specialized training in Tropical Medicine, Dr. Peperstraete managed the HIV business unit at Bristol Myers & Squibb, Singapore.